Pf-06954522 — Competitive Intelligence Brief

Pf-06954522 (pf-06954522) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Small molecule inhibitor. Area: Rare Disease.

marketed Small molecule inhibitor [specific target] Rare Disease

Target snapshot

Pf-06954522 (pf-06954522) — Pfizer.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pf-06954522 TARGET	pf-06954522	Pfizer	marketed	Small molecule inhibitor	[specific target]
Pf-08052666	pf-08052666	Pfizer	marketed	Small molecule inhibitor	Specific protein involved in disease pathways	Unknown
mPnC candidate	mpnc-candidate	Pfizer	marketed	Novel therapeutic agent	Specific protein or receptor involved in disease pathology	TBD
Pf-08046045	pf-08046045	Pfizer	marketed	Small molecule inhibitor	Specific protein involved in cancer cell proliferation	TBD
PF-07321332 Dose 5	pf-07321332-dose-5	Pfizer	marketed	Protease inhibitor	Main protease (MPro) of SARS-CoV-2	Pending regulatory approval
Isauvuconazole group	isauvuconazole-group	Pfizer	marketed	Echinocandin	β-(1,3)-D-glucan synthase	Not yet launched
Talazoparib with enzalutamide	talazoparib-with-enzalutamide	Pfizer	marketed	PARP inhibitor and androgen receptor inhibitor	PARP enzymes and androgen receptor	Not yet launched

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Small molecule inhibitor class)

1. Pfizer · 8 drugs in this class
2. Artcline GmbH · 1 drug in this class
3. Astex Pharmaceuticals, Inc. · 1 drug in this class
4. Rennes University Hospital · 1 drug in this class
5. The First Affiliated Hospital of Soochow University · 1 drug in this class